Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 14/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.97 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.97 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.97 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.97 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tacrine SCHEMBL2330285 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL1044163 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL490750 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL3270 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL7638777 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL2236694 | 0.98 | THRB (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL5580054 | 0.98 | THRB (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL29681895 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL29594645 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL2828 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014140581-A1 | TRANSCRIPTION FACTOR DECOYS | PROCARTA BIOSYSTEMS LTD (GB) | 2014-09-18 | — | — | WO | claimed |
| EP-2552455-A2 | TRANSCRIPTION FACTOR DECOYS | Procarta Biosystems Ltd (GB) | 2013-02-06 | — | — | EP | claimed |
| EP-2533815-A1 | NUCLEIC ACID COMPLEXES | Procarta Biosystems Ltd (GB) | 2012-12-19 | — | — | EP | claimed |
| WO-2011121357-A2 | TRANSCRIPTION FACTOR DECOYS | PROCARTA BIOSYSTEMS LIMITED (GB) | 2011-10-06 | — | — | WO | claimed |
| WO-2011098829-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2011-08-18 | — | — | WO | claimed |
| US-10350299-B2 | Nucleic acid complexes | PROCARTA BIOSYSTEMS LTD. (GB) | 2019-07-16 | — | — | US | disclosed |
| US-20170340745-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD. (GB) | 2017-11-30 | — | — | US | disclosed |
| EP-2552455-B1 | TRANSCRIPTION FACTOR DECOYS | PROCARTA BIOSYSTEMS LTD (GB) | 2016-12-28 | — | — | EP | disclosed |
| WO-2014140581-A1 | TRANSCRIPTION FACTOR DECOYS | PROCARTA BIOSYSTEMS LTD (GB) | 2014-09-18 | — | — | WO | disclosed |
| EP-2552455-A2 | TRANSCRIPTION FACTOR DECOYS | Procarta Biosystems Ltd (GB) | 2013-02-06 | — | — | EP | disclosed |
| EP-2533815-A1 | NUCLEIC ACID COMPLEXES | Procarta Biosystems Ltd (GB) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011121357-A2 | TRANSCRIPTION FACTOR DECOYS | PROCARTA BIOSYSTEMS LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011098829-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350299-B2 | Nucleic acid complexes | ZFR, SUB1, RELA | ACHE 4834/4885BCHE 4569/4885TSHR 2390/4885 |
| US-20170340745-A1 | NUCLEIC ACID COMPLEXES | ZFR, SUB1, RELA | ACHE 4834/4885BCHE 4569/4885TSHR 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.